

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 April 2025 (17.04.2025)



(10) International Publication Number
WO 2025/080631 A1

(51) International Patent Classification:

C07D 498/04 (2006.01) A61K 31/553 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/050451

(22) International Filing Date:

09 October 2024 (09.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/589,453 11 October 2023 (11.10.2023) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly
Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors: **BURNS, Lee, J.**; c/o Eli Lilly and Company,
P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **COLE,
Kevin, P.**; c/o Eli Lilly and Company, P.O. Box 6288, In-
dianapolis, IN 46206-6288 (US). **GONG, Xueqian**; c/o
Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN
46206-6288 (US). **HYMAN, David, Michael**; c/o Eli Lilly
and Company, P.O. Box 6288, Indianapolis, IN 46206-6288
(US). **KJELL, Douglas, P.**; c/o Eli Lilly and Company, P.O.
Box 6288, Indianapolis, IN 46206-6288 (US). **LINDER,
Ryan, J.**; c/o Eli Lilly and Company, P.O. Box 6288, In-
dianapolis, IN 46206-6288 (US). **PENG, Sheng-Bin**; c/o
Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN
46206-6288 (US). **SI, Chong**; c/o Eli Lilly and Company,
P.O. Box 6288, Indianapolis, IN 46206-6288 (US).

(74) Agent: **D'HUE, Cedric, A.** et al.; c/o Eli Lilly and Compa-
ny, P. O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: PROCESS FOR MAKING A KRAS G12C INHIBITOR



(57) Abstract: The present disclosure provides processes that can be used to prepare the compound of Formula I, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the compound of Formula I, wherein a Michael adduct impurity is present in an amount of less than 0.3% as measured by HPLC Analysis, and methods of treating cancer using the compound of Formula I and pharmaceutical compositions.



WO 2025/080631 A1